Expression of cell-cycle regulatory proteins cyclin D1, cyclin E, and their inhibitor p21 WAF1/CIP1 in gastric cancer

Journal of Pathology

Volumn 189, Issue 2, 1999, Pages 186-193

  Müller, Wolfram ^a   Noguchi, Tsuyoshi ^a   Wirtz, Hans Christian ^a   Hommel, Gerhard ^b   Gabbert, Helmut E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Heinrich Heine Univ of Dusseldorf ^*

Author keywords

Cyclin D1; Cyclin E; Gastric cancer; Immunohistochemistry; P21; Prognosis

Indexed keywords

CYCLIN D1; CYCLIN E; PROTEIN P21;

CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 17944388015     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199910)189:2<186::AID-PATH418>3.0.CO;2-L     Document Type: Review

References (58)

1. Betticher DC. Cyclin D1, another molecule of the year? Ann Oncol 1996; 7: 223-225.
2. Barnes DM. Cyclin D1 in mammary carcinoma. J Pathol 1997; 181: 267-269.
3. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 1995; 1: 1257-1260.
4. Keyomarsi K, Conte D, Toyofuku W, Fox P. Deregulation of cyclin E in breast cancer. Oncogene 1995; 11: 941-950.
5. Bates S, Peters G. Cyclin D1 as a cellular proto-oncogene. Cancer Biol 1995; 6: 73-82.
6. Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 1995; 15: 2600-2611.
7. Lewin B. Driving the cell cycle: M phase kinase, its partners, and substrates. Cell 1990; 61: 743-752.
8. Strauss M, Lukas J, Barter KJ. Unrestricted cell cycling and cancer. Nature Med 1995; 1: 1245-1246.
9. Dou Q-P, Pardee AB, Keomarsi K, Steeg P. Cyclin E - a better prognostic marker for breast cancer than cyclin D1? Nature Med 1996; 2: 254.
10. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994; 79: 551-554.
11. Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993; 7: 1559-1571.
12. Lovee H, Sewing A, Lucibello FC, Muller R, Moroy T. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle and malignant transformation. Oncogene 1994; 9: 323-326.
13. Barbareschi M, Pelosio P, Caffo O, et al. Cyclin D1 gene amplification and overexpression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int J Cancer (Pred Oncol) 1997; 74: 171-174.
14. McIntosh GG, Anderson JJ, Milton I, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995; 11: 885-891.
15. Michalides R, Hageman P, van Tinteren H, et al. A clinicopathological study on overexpression of cyclin D1 and p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996; 73: 728-734.
16. van Diest PJ, Michalides R, Jannink I, et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognosis. Am J Pathol 1997; 150: 705-711.
17. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992; 52: 2980-2983.
18. Nakagawa H, Zukerberg L, Togawa K, Meltzer SJ, Nishihara T, Rustgi AK. Human cyclin D1 oncogene and esophageal squamous cell carcinoma. Cancer 1995; 76: 541-549.
19. Gillet C, Fantl V, Fisher C, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-1817.
20. Gansauge S, Gansauge F, Ramadani M, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997; 54: 1634-1637.
21. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG, Korc M. Increased cyclin D1 in human pancreatic cancer is associated with decreased survival. Oncology 1998; 55: 363-369.
22. Maeda K, Chung Y, Ogawa M, et al. Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 1998; 55: 145-151.
23. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54: 380-385.
24. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27kipl and cyclin, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997; 3: 222-225.
25. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-825.
26. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
27. Harper JW, Elledge SJ, Keyomarsi K, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995; 6: 387-400.
28. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature (London) 1993; 366: 701-704.
29. Waldmann T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-5190.
30. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994; 54: 3391-3395.
31. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang X-F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995; 92: 5545-5549.
32. DiGuiseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147: 884-888.
33. Wang J, Walsh K. Resistance to apoptosis conferred by cdk inhibitors during myocyte differentiation. Science 1996; 273: 359-361.
34. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996; 10: 1945-1952.
35. Caffo O, Doglioni C, Veronese S, et al. Prognostic value of p21WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996; 2: 1591-1599.
36. Johnson EA, Davidson AG, Hostetter RB, Cook LL, Thomas EM, Quinlan DC. The expression of waf-1 in node-negative infiltrating ductal breast carcinoma. Proc Am Assoc Cancer Res 1996; 37: 569.
37. Caputi M, Esposito V, Baldi A, et al. p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 1998; 18: 213-217.
38. Lu X, Toki T, Konishi I, Nikaido T, Fujii S. Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix. Cancer 1998; 82: 2409-2417.
39. Diab SG, Yu Y-Y, Hilsenbeck SG, Allred DC, Elledge RM. WAF1/CIP1 protein expression in human breast tumours. Breast Cancer Res Treat 1997; 43: 99-103.
40. Gomyo Y, Ikeda M, Osaki M, et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997; 79: 2067-2072.
41. Ogawa M, Maeda K, Onoda N, Chung Y-S, Sowa M. Loss of p21WAF1/ CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer 1997; 75: 1617-1620.
42. Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 1996; 180: 122-128.
43. Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin E in human gastric adenomas and adenocarcinomas: correlation with proliferative activity and p53 status. J Exp Ther Oncol 1996; 1: 88-94.
44. International Union Against Cancer. TNM Classification of Malignant Tumors. 4th edn. 2nd rev. Berlin: Springer-Verlag, 1992: 47-50.
45. Oota K, Sobin LH. Histological Typing of Gastric and Oesophageal Tumours. International Histological Classification of Tumours, 18. Geneva: WHO, 1977.
46. Lauren P. The two histological main types of gastric carcinomas: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Immunol Scand 1965; 64: 31-49.
47. Gabbert HE, Meier S, Gerharz CD, Hommel G. Incidence and prognostic significance of vascular invasion in 529 gastric cancer patients. Int J Cancer 1991; 49: 203-207.
48. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
49. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Data. New York: Wiley, 1980.
50. Akama Y, Yasui W, Yokozaki H, et al. Frequent amplification of the cyclin E gene in human gastric carcinomas. Jpn J Cancer Res 1995; 86: 617-621.
51. Müller W, Schneiders A, Meier S, Hommel G, Gabbert HE. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer 1996; 74: 759-765.
52. Cordon-Cardo C. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-560.
53. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55: 975-978.
54. Chen X, Bargonetti J, Prives C. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 1995; 55: 4257-4263.
55. Upadhyay S, Li G, Liu H, Chen YQ, Sarkar FH, Kim H-RC. bcl-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells. Cancer Res 1995; 55: 4520-4524.
56. Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995; 76: 720-726.
57. Müller W, Schneiders A, Hommel G, Gabbert HE. Prognostic value of bcl-2 expression in gastric cancer. Anticancer Res 1998; 18: 4699-4704.
58. Erber R, Klein W, Andl T, et al. Aberrant p21 CIP1/WAF1 protein accumulation in head-and-neck cancer. Int J Cancer (Pred Oncol) 1997; 74: 383-389.